Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
S Claiborne JohnstonPierre AmarencoHans DenisonScott R EvansAnders HimmelmannStefan JamesMikael KnutssonPer LadenvallCarlos A MolinaYongjun Wangnull nullPublished in: The New England journal of medicine (2020)
Among patients with a mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score ≤5) or TIA who were not undergoing intravenous or endovascular thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor-aspirin than with aspirin alone, but the incidence of disability did not differ significantly between the two groups. Severe bleeding was more frequent with ticagrelor. (Funded by AstraZeneca; THALES ClinicalTrial.gov number, NCT03354429.).
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- low dose
- atrial fibrillation
- cardiovascular events
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- high dose
- multiple sclerosis
- pulmonary embolism
- liver failure
- anti inflammatory drugs
- risk factors
- cardiovascular disease
- early onset
- intensive care unit
- aortic dissection
- respiratory failure
- type diabetes
- acute ischemic stroke